Mold, ceiling holes cited in CP Pharma warning
Mold in a class 100 production room and holes in a ceiling at a CP Pharmaceuticals plant in Wrexham, U.K., are part of a list of violations identified by FDA inspectors in Warning Letter 320-11-002.
Mold in a class 100 production room and holes in a ceiling at a CP Pharmaceuticals plant in Wrexham, U.K., are part of a list of violations identified by FDA inspectors in Warning Letter 320-11-002. The letter follows a July inspection. Because CP took more than 15 days to reply to the Form 483 report issued after the inspection, the regulator doesn't acknowledge them in the warning.
The mold and the holes are some of the building-related inspection details the FDA documents. Inspectors note the holes in the ceiling of a freeze dryer room and say they saw outside light entering in the vicinity of the ventilation system. The letter says the room is subject to regular maintenance, yet the holes remain despite an incident report from late last year that describes them. Another item from the incident report: bubbling vinyl and disintegration of the wall beneath it.
Inspectors found more mold in a class 10,000 area, almost a year after it was first seen there. The warning
Related News
-
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance